An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

NCT03329846 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Skin Cancer

Interventions

DRUG: BMS-986205
BIOLOGICAL: Nivolumab
DRUG: Placebo

Sponsor

Bristol-Myers Squibb